屈臣氏集團:2012年至今已投資16億美元加速數碼轉型
屈臣氏集團宣佈,與科技合作夥伴Revieve攜手開發人工智能皮膚分析服務Skin Advisor,計劃明年上半年於亞洲市場推出。
集團指,該服務於英國Superdrug推出以來,Superdrug平均訂單金額增加超過20%,銷售轉換率更錄雙倍增長。
集團又指,自2012年至今已投資16億美元加速數碼轉型。屈臣氏集團亞洲首席數碼總監吳逸羣表示,未來將繼續以客爲先,研發更多技術方案,爲顧客提供最完善O+O(線下及線上)購物體驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.